SELLAS Life Sciences Reports Clinical Trial Progress
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 52 minutes ago
0mins
Should l Buy SLS?
Source: stocktwits
- Clinical Trial Death Events: As of May 11, 2026, the REGAL study by SELLAS Life Sciences has recorded 78 deaths, with the 80th event expected imminently, which will trigger data analysis and result disclosure, marking a significant advancement in the treatment of acute myeloid leukemia (AML).
- Positive Stock Reaction: Following the CEO's announcement of imminent data release, SELLAS shares surged nearly 8% in after-hours trading, reflecting strong investor optimism regarding the upcoming clinical data and confidence in the company's future potential.
- Optimistic Survival Expectations: CEO Angelos Stergiou expressed at the Stifel 2026 Targeted Oncology Virtual Forum that survival times in the REGAL trial appear “longer than expected,” which may increase the probability of study success, further bolstering investor confidence.
- Market Sentiment Analysis: On Stocktwits, retail sentiment around SLS remained in the 'extremely bullish' territory, despite a decrease in message volume, with investors generally anticipating a major rally upon reaching the 80th event milestone, indicating high market interest in the company's future developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLS
Wall Street analysts forecast SLS stock price to fall
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 7.290
Low
7.00
Averages
7.25
High
7.50
Current: 7.290
Low
7.00
Averages
7.25
High
7.50
About SLS
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SELLAS Life Sciences Reports Clinical Trial Progress
- Clinical Trial Death Events: As of May 11, 2026, the REGAL study by SELLAS Life Sciences has recorded 78 deaths, with the 80th event expected imminently, which will trigger data analysis and result disclosure, marking a significant advancement in the treatment of acute myeloid leukemia (AML).
- Positive Stock Reaction: Following the CEO's announcement of imminent data release, SELLAS shares surged nearly 8% in after-hours trading, reflecting strong investor optimism regarding the upcoming clinical data and confidence in the company's future potential.
- Optimistic Survival Expectations: CEO Angelos Stergiou expressed at the Stifel 2026 Targeted Oncology Virtual Forum that survival times in the REGAL trial appear “longer than expected,” which may increase the probability of study success, further bolstering investor confidence.
- Market Sentiment Analysis: On Stocktwits, retail sentiment around SLS remained in the 'extremely bullish' territory, despite a decrease in message volume, with investors generally anticipating a major rally upon reaching the 80th event milestone, indicating high market interest in the company's future developments.
See More
Morgan Stanley Increases SLS Stake by Nearly 50%
- Institutional Buying Surge: Morgan Stanley increased its SLS stake by nearly 50% in Q1, adding over 445,000 shares to reach a total of 1.34 million shares valued at $5.65 million, indicating strong confidence in Sellas Life Sciences and potentially driving further stock price appreciation.
- Clinical Trial Milestone: Sellas' Phase 3 Regal trial reached 78 events as of May 11, leaving just two events before the threshold for final data analysis, which is expected to accelerate data release and heighten market interest in its AML treatment options.
- Cash Position Strength: Sellas ended Q1 with approximately $107.1 million in cash and cash equivalents, receiving an additional $7.5 million from warrant exercises in Q2, and established a new at-the-market equity facility that could raise up to $150 million, enhancing its R&D capabilities.
- Investor Sentiment Soars: Retail sentiment for SLS is extremely bullish, with a 114% increase in chatter over the past week, reflecting high market anticipation for upcoming investor conferences and clinical progress, which may further drive stock price increases.
See More
Sellas Life Sciences Stock Soars 48% Ahead of Key Conferences
- Stock Surge: Sellas Life Sciences (SLS) shares have surged 48% this week, marking its best performance in over four months, driven by anticipation surrounding upcoming cancer conferences and investor interest in its AML drug pipeline.
- Clinical Trial Progress: The Phase 3 Regal trial has reached 78 events, just two short of the 80 required for final analysis, with expectations to soon enter database lock and unblinding procedures, which could significantly impact the company's future stock performance.
- Strong Financial Position: Sellas ended Q1 with $107.1 million in cash and raised an additional $7.5 million through warrant exercises, while establishing a new at-the-market equity facility to potentially raise up to $150 million, enhancing its financial flexibility for future developments.
- Institutional Buying: BlackRock increased its stake in Sellas by 62% as of March 31, bringing its total to 12.2 million shares valued at $51.6 million, with other institutions also reporting increased positions, reflecting strong market confidence in Sellas' prospects.
See More
Sellas Life Sciences Stock Soars 25% Amid Institutional Buying and AML Data Catalyst
- Stock Surge: Sellas Life Sciences' shares soared 25% on Wednesday, marking its best single-day performance in over two months, primarily driven by BlackRock's 62% stake increase, reflecting strong market confidence in the company.
- Clinical Trial Progress: As of May 11, Sellas' Phase 3 Regal AML study reached 78 events, just two away from final data disclosure, with the CEO highlighting this moment as crucial for potential transformative treatment for AML patients.
- Strong Financial Position: Sellas ended Q1 with $107.1 million in cash and equivalents and secured an additional $7.5 million from warrant exercises in Q2, while establishing a new at-the-market equity facility to raise up to $150 million, although no shares have been sold yet.
- Second AML Program: Sellas' second AML program, SLS009, has begun dosing newly diagnosed high-risk patients in a Phase 2 study, with early data showing promising effects on AML cells, and topline data expected in Q4, further enhancing market anticipation.
See More
Nebius Reports 654% Revenue Surge; Cisco Raises AI Order Forecast to $9 Billion
- Nebius Revenue Surge: Nebius reported a staggering 684% year-over-year increase in Q1 revenue, reaching $399 million, surpassing Wall Street's estimate of $388 million, indicating strong demand in AI infrastructure, with a projected annual recurring revenue of $7 billion to $9 billion for 2026, solidifying its market position.
- Cisco AI Order Forecast Raised: Cisco raised its AI-related infrastructure order forecast for 2026 from $5 billion to $9 billion, reflecting robust demand for AI hardware, while reporting a 12% increase in Q3 revenue to $15.8 billion, exceeding analyst expectations, showcasing the company's success in its transformation.
- Sellas Cancer Research Progress: Sellas Life Sciences updated on its Phase 3 REGAL study for acute myeloid leukemia, nearing the final event threshold for key data readout, and has initiated a Phase 2 trial for high-risk AML patients, demonstrating its potential in cancer treatment.
- Strong Stock Market Performance: Stocks of Nebius, Cisco, and Sellas reached fresh 52-week highs, with gains of over 147%, 32%, and 73% respectively, as investors recognized tangible progress in AI infrastructure and drug development, with retail sentiment shifting to 'extremely bullish'.
See More
U.S. Stocks Hit Record Highs, Tech Stocks Lead Gains
- Tech Stock Surge: The Nasdaq rose 1.4% and the S&P 500 gained 0.6%, both reaching record highs, indicating strong performance in tech stocks, particularly with NVIDIA hitting all-time highs, reflecting increased investor confidence in the technology sector.
- Rising Inflation Pressures: The producer price index surged 6% year-over-year in April, marking the highest level in four years and the sharpest monthly increase since 2022, indicating heightened cost pressures for producers that could influence future monetary policy and raise concerns about interest rate hikes.
- New Fed Chair Confirmation: The U.S. Senate confirmed Kevin Warsh as the 17th chair of the Federal Reserve, and while he advocates for lower rates, the current inflation signals have led to market uncertainty regarding future policy directions, potentially increasing market volatility.
- Energy Market Trends: Brent crude oil prices settled near $104.85 per barrel, as fears of rising U.S. interest rates dampened global demand outlook; however, the International Energy Agency warned that global oil supply could remain below demand until 2026 due to ongoing disruptions in the Middle East.
See More
SELLAS Life Sciences Reports Clinical Trial Progress
- Clinical Trial Death Events: As of May 11, 2026, the REGAL study by SELLAS Life Sciences has recorded 78 deaths, with the 80th event expected imminently, which will trigger data analysis and result disclosure, marking a significant advancement in the treatment of acute myeloid leukemia (AML).
- Positive Stock Reaction: Following the CEO's announcement of imminent data release, SELLAS shares surged nearly 8% in after-hours trading, reflecting strong investor optimism regarding the upcoming clinical data and confidence in the company's future potential.
- Optimistic Survival Expectations: CEO Angelos Stergiou expressed at the Stifel 2026 Targeted Oncology Virtual Forum that survival times in the REGAL trial appear “longer than expected,” which may increase the probability of study success, further bolstering investor confidence.
- Market Sentiment Analysis: On Stocktwits, retail sentiment around SLS remained in the 'extremely bullish' territory, despite a decrease in message volume, with investors generally anticipating a major rally upon reaching the 80th event milestone, indicating high market interest in the company's future developments.
See More
Morgan Stanley Increases SLS Stake by Nearly 50%
- Institutional Buying Surge: Morgan Stanley increased its SLS stake by nearly 50% in Q1, adding over 445,000 shares to reach a total of 1.34 million shares valued at $5.65 million, indicating strong confidence in Sellas Life Sciences and potentially driving further stock price appreciation.
- Clinical Trial Milestone: Sellas' Phase 3 Regal trial reached 78 events as of May 11, leaving just two events before the threshold for final data analysis, which is expected to accelerate data release and heighten market interest in its AML treatment options.
- Cash Position Strength: Sellas ended Q1 with approximately $107.1 million in cash and cash equivalents, receiving an additional $7.5 million from warrant exercises in Q2, and established a new at-the-market equity facility that could raise up to $150 million, enhancing its R&D capabilities.
- Investor Sentiment Soars: Retail sentiment for SLS is extremely bullish, with a 114% increase in chatter over the past week, reflecting high market anticipation for upcoming investor conferences and clinical progress, which may further drive stock price increases.
See More
Sellas Life Sciences Stock Soars 48% Ahead of Key Conferences
- Stock Surge: Sellas Life Sciences (SLS) shares have surged 48% this week, marking its best performance in over four months, driven by anticipation surrounding upcoming cancer conferences and investor interest in its AML drug pipeline.
- Clinical Trial Progress: The Phase 3 Regal trial has reached 78 events, just two short of the 80 required for final analysis, with expectations to soon enter database lock and unblinding procedures, which could significantly impact the company's future stock performance.
- Strong Financial Position: Sellas ended Q1 with $107.1 million in cash and raised an additional $7.5 million through warrant exercises, while establishing a new at-the-market equity facility to potentially raise up to $150 million, enhancing its financial flexibility for future developments.
- Institutional Buying: BlackRock increased its stake in Sellas by 62% as of March 31, bringing its total to 12.2 million shares valued at $51.6 million, with other institutions also reporting increased positions, reflecting strong market confidence in Sellas' prospects.
See More
Sellas Life Sciences Stock Soars 25% Amid Institutional Buying and AML Data Catalyst
- Stock Surge: Sellas Life Sciences' shares soared 25% on Wednesday, marking its best single-day performance in over two months, primarily driven by BlackRock's 62% stake increase, reflecting strong market confidence in the company.
- Clinical Trial Progress: As of May 11, Sellas' Phase 3 Regal AML study reached 78 events, just two away from final data disclosure, with the CEO highlighting this moment as crucial for potential transformative treatment for AML patients.
- Strong Financial Position: Sellas ended Q1 with $107.1 million in cash and equivalents and secured an additional $7.5 million from warrant exercises in Q2, while establishing a new at-the-market equity facility to raise up to $150 million, although no shares have been sold yet.
- Second AML Program: Sellas' second AML program, SLS009, has begun dosing newly diagnosed high-risk patients in a Phase 2 study, with early data showing promising effects on AML cells, and topline data expected in Q4, further enhancing market anticipation.
See More
Nebius Reports 654% Revenue Surge; Cisco Raises AI Order Forecast to $9 Billion
- Nebius Revenue Surge: Nebius reported a staggering 684% year-over-year increase in Q1 revenue, reaching $399 million, surpassing Wall Street's estimate of $388 million, indicating strong demand in AI infrastructure, with a projected annual recurring revenue of $7 billion to $9 billion for 2026, solidifying its market position.
- Cisco AI Order Forecast Raised: Cisco raised its AI-related infrastructure order forecast for 2026 from $5 billion to $9 billion, reflecting robust demand for AI hardware, while reporting a 12% increase in Q3 revenue to $15.8 billion, exceeding analyst expectations, showcasing the company's success in its transformation.
- Sellas Cancer Research Progress: Sellas Life Sciences updated on its Phase 3 REGAL study for acute myeloid leukemia, nearing the final event threshold for key data readout, and has initiated a Phase 2 trial for high-risk AML patients, demonstrating its potential in cancer treatment.
- Strong Stock Market Performance: Stocks of Nebius, Cisco, and Sellas reached fresh 52-week highs, with gains of over 147%, 32%, and 73% respectively, as investors recognized tangible progress in AI infrastructure and drug development, with retail sentiment shifting to 'extremely bullish'.
See More
U.S. Stocks Hit Record Highs, Tech Stocks Lead Gains
- Tech Stock Surge: The Nasdaq rose 1.4% and the S&P 500 gained 0.6%, both reaching record highs, indicating strong performance in tech stocks, particularly with NVIDIA hitting all-time highs, reflecting increased investor confidence in the technology sector.
- Rising Inflation Pressures: The producer price index surged 6% year-over-year in April, marking the highest level in four years and the sharpest monthly increase since 2022, indicating heightened cost pressures for producers that could influence future monetary policy and raise concerns about interest rate hikes.
- New Fed Chair Confirmation: The U.S. Senate confirmed Kevin Warsh as the 17th chair of the Federal Reserve, and while he advocates for lower rates, the current inflation signals have led to market uncertainty regarding future policy directions, potentially increasing market volatility.
- Energy Market Trends: Brent crude oil prices settled near $104.85 per barrel, as fears of rising U.S. interest rates dampened global demand outlook; however, the International Energy Agency warned that global oil supply could remain below demand until 2026 due to ongoing disruptions in the Middle East.
See More
